A good Q4 coming up with 9% revenue and 15% EPS growth 2025 guidance likely to show accelerating gro...
Cost-effective coatings for hydrogen and metallisation applications Seizing opportunities in Chinese...
We forecast Q4 revenue of NOK 243m, +15% y-o-y Doro acquisition closed, could lift '28e EBITA by ~12...
Q4 not likely to be a game-changer New design win with Dell opens large new segment Ambition of 50-6...
This afternoon just before market close, Føroya Banki announced its 2025 net profit guidance range o...
Redeye comments on the outcome of Ngenic’s rights issue, which was subscribed to 88%, injecting Ngen...
According to preliminary information, annual EBITDA will be EUR 4-6m in 2024 (old guidance EUR 4-8m,...
Redeye provides a brief comment on the final rights issue terms announced yesterday.
Redeye revisits some assumptions related to financing and likelihood of approval following the progr...
SEK 120+7m retrofit order to be delivered in 2025-2035 Covers our '25e-'28e Retrofit assumptions, ~1...
Q4e: 15% organic sales growth y-o-y, 11% adj. EBITA margin Expect a solid Q4, partly on light comps ...
Redeye gives its preview on OssDsign’s Q3 2024 report, due on February 4.
Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
Redeye offers a preview of Polygien's Q4 results set to be released on February 13.
The greatest excitement regarding Aspo's Q4 results faded when the company downgraded its full-year ...
We estimate 2024 net profit of DKK 310m, at the upper end of the recently updated 2024 guidance rang...
Inför Q4-rapporten räknar Analysguiden med en svagare efterfrågan, särskilt inom industrisegmentet, ...
Preliminary Q4 sales SEK 8.2m, cash balance SEK 17m '25e-'26e sales and EBIT unchanged, EPS changes ...
Q4 due on 13 February Negative organic growth but +14% adj.
Exposure to fast-growing and non-cyclical infrastructure We forecast 23% EBITA CAGR in '23-'26e, ~40...